BioTech Social launches funding portal for life science startups

BioTech Social Inc. launched BioTech Funding Portal, an SEC-registered, FINRA-member crowdfunding platform focused exclusively on life science companies. The move gives biotech, pharma, med-tech and related startups a new way to raise up to $5 million in a 12-month period from both accredited and non-accredited investors.

Why it matters: - Life science startups often face long development cycles, heavy regulatory burdens and funding gaps before traditional investors step in. - BioTech Funding Portal is built to connect those companies with communities that already care about their science, including patient groups, researchers and disease foundations. - Regulation Crowdfunding can allow eligible companies to raise up to $5 million in 12 months from a broad investor base.

What happened: - BioTech Social Inc. launched BioTech Funding Portal on June 22, 2026. - The platform is SEC-registered and a FINRA member. - The portal is limited to life science companies seeking capital through Regulation Crowdfunding. - The launch coincided with BIO International Convention 2026 in San Diego.

The details: - The platform targets companies in biotech, pharmaceuticals, advanced therapeutics, medical devices, veterinary science, diagnostics and other life science ventures. - Those businesses may face review from the FDA, USDA and, where applicable, EPA. - BioTech Social says the portal is designed to help issuers communicate science in plain English and meet Regulation Crowdfunding disclosure requirements. - The company also says the platform is intended to support responsible, compliant engagement by patient advocacy groups, scientific societies, disease foundations, clinicians and researchers. - BioTech Social lists FPRD #334156 for BioTech Funding Portal. - The company says eligible offerings will be speculative, illiquid and high risk, including the possible loss of the entire investment. - The company says offering materials, not the press release, will govern any securities offering filed with the U.S. Securities and Exchange Commission.

Between the lines: - The launch is aimed at a market segment that can be hard to serve with standard venture or institutional capital because of long timelines and specialized disclosure needs. - The platform’s niche focus suggests BioTech Social is betting that mission-aligned investors may be more willing to back regulated science-heavy ventures than generalist retail audiences. - CEO and Co-Founder Dr. Neva West framed the effort as a way to help companies with unmet medical needs reach clinical and regulatory milestones. - Chair and Co-Founder Brian P. Christie said the goal is to help companies cross the “valley of death” between early scientific promise and traditional institutional financing.

What's next: - Life science companies can learn more and prospective investors can create an account at the platform. - BioTech Social appears positioned to use the portal to expand capital formation for biotech, med-tech, pharma-tech, digital health and diagnostics companies. - The company is likely to use the platform to attract issuers and investors seeking a regulated crowdfunding path tailored to science-driven businesses.

The bottom line: - BioTech Social is trying to make Regulation Crowdfunding a more usable capital source for life science companies that often struggle to raise money before reaching major clinical or regulatory milestones.